Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Sept 18 (Reuters) — Eli Lilly and Company: U.s. Fda Approves Inluriyo (Imlunestrant) In Combination With Verzenio (Abemaciclib) For Adults With Er+, Her2-, Esr1-mutated Advanced Or Metastatic Breast Cancer Eli Lilly - Inluriyo With Verzenio Now Available In The United States Source text:... Further company coverage: LL
FDA granted full approval for Inluriyo (imlunestrant) with Verzenio (abemaciclib) in ESR1-mutated ER+, HER2- advanced breast cancer. Label covers adults with progression following at least one line of endocrine therapy, with mutation confirmed by an FDA-authorized test. EMBER-3 trial showed median PFS of 11.1 months vs
FDA approval covers Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer.